|
|
| | INNO206 Basic information |
| Product Name: | INNO206 | | Synonyms: | Aldoxorubicin;Aldoxorubicin (INNO-206);N-[(E)-[1-[(2S,4S)-4-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]-2-hydroxyethylidene]amino]-6-(2,5-dioxopyrrol-1-yl)hexanamide;(E)-N’-[1-[(2S,4S)-4-[[(2R,4S,5S,6S)-4-Amino-5-hydroxy-6-methyl-2-tetrahydropyranyl]oxy]-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydro-2-tetracenyl]-2-hydroxyethylidene]-6-(2,5-dioxo-2,5-dihydro-1-pyrrolyl)hexanehydrazide;Aldoxorubicin Aldoxorubicin;1H-Pyrrole-1-hexanoic acid, 2,5-dihydro-2,5-dioxo-, (2E)-2-[1-[(2S,4S)-4-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl]-2-hydroxyethylidene]hydrazide;DoxorubicinImpurity16Trifluoroacetate;N'-((E)-1-((2S,4S)-4-(((2R,4S,5S,6S)-4-Amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-2-yl)-2-hydroxyethylidene)-6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanehydrazide | | CAS: | 1361644-26-9 | | MF: | C37H42N4O13 | | MW: | 750.75 | | EINECS: | | | Product Categories: | | | Mol File: | 1361644-26-9.mol |  |
| | INNO206 Chemical Properties |
| density | 1.60±0.1 g/cm3(Predicted) | | storage temp. | -80°, stored under nitrogen,unstable in solution, ready to use. | | solubility | DMSO : 75 mg/mL (99.90 mM) | | form | Solid | | pka | 7.36±0.60(Predicted) | | color | Purple to purplish red |
| | INNO206 Usage And Synthesis |
| Biological Activity | Aldoxorubicin (INNO-206) is an albumin-bound prodrug of doxorubicin, a DNA topoisomerase II inhibitor, released from albumin under acidic conditions. It has potent antitumor activity in various cancer cell lines and mouse tumor models. | | in vitro | Aldoxorubicin (INNO-206) (0.27 to 2.16 μM) inhibits blood vessel formation and reduces multiple myeloma cell growth in a pH-dependent fashion. | | in vivo | Aldoxorubicin (INNO-206) (10.8 mg/kg, i.v.) shows significantly smaller tumor volumes and IgG levels on days 28, and is well tolerated with 90% of mice surviving until the termination of the study in the mice bearing the LAGκ-1A tumor. | | target | | Topoisomerase II | Daunorubicins/Doxorubicins | |
| | INNO206 Preparation Products And Raw materials |
|